23:47 , May 23, 2019 |  BC Innovations  |  Tools & Techniques

As polygenic risk scores mature, opportunities emerge for disease interception

With comprehensive genetic risk profiling inching closer to clinical use, the biggest opportunity for drug developers could be the new territory it opens up in disease prevention and interception, particularly for common diseases. Much of...
00:41 , Apr 6, 2019 |  BC Extra  |  Politics & Policy

CFIUS drawing line in sand on personal data

The Trump administration has further reinforced which kinds of life science investments will be off limits for foreign investors, as reports emerge that CFIUS is compelling two more Chinese firms to relinquish control over companies...
19:25 , Dec 21, 2018 |  BC Week In Review  |  Company News

GSK, Pfizer JV allows both pharmas to focus on innovation

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) took the first step toward splitting up the pharma's consumer healthcare and innovative R&D businesses by agreeing to form a consumer healthcare joint venture with Pfizer Inc. (NYSE:PFE). The British pharma...
14:04 , Dec 19, 2018 |  BC Extra  |  Company News

GSK, Pfizer JV allows both pharmas to focus on innovation

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) took the first step toward splitting up the pharma's consumer healthcare and innovative R&D businesses by agreeing to form a consumer healthcare joint venture with Pfizer Inc. (NYSE:PFE). The British pharma...
18:04 , Dec 7, 2018 |  BC Week In Review  |  Company News

GSK gains Zejula, immuno-oncology portfolio in $5.1B Tesaro takeout

Although it's inheriting a portfolio of cancer compounds from Tesaro Inc. (NASDAQ:TSRO) that fall squarely into competitive areas, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects to transform the candidates, including Zejula niraparib, into best-in-class therapies under Hal...
00:50 , Dec 4, 2018 |  BC Extra  |  Company News

GSK gains Zejula, immuno-oncology pipeline in $5.1B Tesaro acquisition

Although it's inheriting a portfolio of cancer compounds from Tesaro Inc. (NASDAQ:TSRO) that fall squarely into competitive areas, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects to transform the candidates, including Zejula niraparib, into best-in-class therapies under Hal...
23:44 , Nov 19, 2018 |  BC Extra  |  Company News

Management tracks: Brickell, Genevant

Dermatology company Brickell Biotech Inc. (Boulder, Colo.) hired Robert Brown as CEO, effective Jan. 1. He will replace co-founder and CEO Reginald Hardy, who will remain on the board and serve as special adviser to...
21:04 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

FDA approves direct-to-consumer test, warns against others

After authorizing a genetic test from 23andMe Inc. (Mountain View, Calif.), FDA issued a warning against using unapproved tests to guide medical decisions. On Oct. 31, FDA said the Personal Genome Service Pharmacogenetic Reports test...
18:16 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Real-world data play RDMD raises $3M seed round

RDMD (San Francisco, Calif.) raised $3 million on Aug. 20 in a seed round led by new investor Lux Capital, with participation from existing investor Village Globe and new investors First Round's Healthcare Co-Op, Garuda...
11:02 , Aug 20, 2018 |  BC Extra  |  Financial News

Real-world data play RDMD raises $3M seed round

RDMD (San Francisco, Calif.) raised $3 million in a seed round led by new investor Lux Capital, with participation from existing investor Village Globe and new investors First Round's Healthcare Co-Op, Garuda and Shasta Ventures....